{"title":"Farmaci da banco\/\/\/Disturbi gastrointestinali\/\/\/Acidità, Bruciore e Reflusso","description":null,"products":[{"product_id":"gaviscon-gusto-fragola-24-compresse-masticabili-acquista-online-su-farmaclick","title":"Gaviscon Strawberry Flavor 24 Chewable Tablets | Buy Online at Farmaclick","description":"\u003ch2\u003eWhat is Gaviscon Strawberry Flavour 24 Chewable Tablets\u003c\/h2\u003e\u003ch2\u003eTHERAPEUTIC CATEGORY\u003c\/h2\u003e\u003cp\u003ePeptic ulcer and gastro-oesophageal reflux disease (GORD) treatment.\u003c\/p\u003e\u003ch2\u003eACTIVE INGREDIENTS\u003c\/h2\u003e\u003cp\u003esodium alginate; sodium bicarbonate.\u003c\/p\u003e\u003ch2\u003eEXCIPIENTS\u003c\/h2\u003e\u003cp\u003eMint flavour chewable tablets: mannitol (E421), calcium carbonate, magnesium stearate, copovidone, aspartame (E951), acesulfame potassium, macrogol 20,000, mint flavouring.\u003c\/p\u003e\u003cp\u003eStrawberry flavour chewable tablets: xylitol, mannitol (E421), calcium carbonate, macrogol 20,000, strawberry flavouring, aspartame (E951), magnesium stearate, red iron oxide.\u003c\/p\u003e\u003cp\u003eOral suspension: calcium carbonate, carbomers, methyl parahydroxybenzoate (E218), propyl parahydroxybenzoate (E216), sodium saccharin, fennel flavouring, sodium hydroxide, erythrosine, purified water.\u003c\/p\u003e\u003cp\u003eMint flavour oral suspension: calcium carbonate, carbomers, methyl parahydroxybenzoate (E218), propyl parahydroxybenzoate (E216), sodium saccharin, mint flavouring, sodium hydroxide, purified water.\u003c\/p\u003e\u003cp\u003eOral powder: calcium carbonate, silicon dioxide, granular anhydrous citric acid, mint flavouring, aspartame (E951), macrogol 20,000, macrogol 400 fruit, passion fruit flavouring, acesulfame potassium (E950), xylitol.\u003c\/p\u003e\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\u003cp\u003eSymptomatic treatment of occasional heartburn.\u003c\/p\u003e\u003ch2\u003eCONTRAINDICATIONS\/SIDE EFFECTS\u003c\/h2\u003e\u003cp\u003eHypersensitivity to the active ingredients or any of the excipients listed, such as methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) (parabens).\u003c\/p\u003e\u003ch2\u003eDOSAGE\u003c\/h2\u003e\u003cp\u003e\u0026gt;\u0026gt;Chewable tablets (strawberry flavour).\u003c\/p\u003e\u003cp\u003eAdults and adolescents (12-18 years): 1-2 tablets of 500 mg + 267 mg after meals and at bedtime.\u003c\/p\u003e\u003cp\u003e2-4 tablets of 250 mg + 133.5 mg after meals and at bedtime.\u003c\/p\u003e\u003cp\u003eMethod of administration: for oral administration.\u003c\/p\u003e\u003cp\u003eThe tablets must be chewed well (they can be broken up and chewed little by little).\u003c\/p\u003e\u003cp\u003eA little water can be drunk afterwards.\u003c\/p\u003e\u003cp\u003e\u0026gt;\u0026gt;Oral suspension.\u003c\/p\u003e\u003cp\u003eAdults and adolescents (12-18 years): 10-20 ml (second to fourth mark on the measuring cup or 2-4 measuring spoons or 1-2 single-dose sachets) after meals and at bedtime.\u003c\/p\u003e\u003cp\u003eMethod of administration: for oral administration.\u003c\/p\u003e\u003cp\u003eShake the suspension before use.\u003c\/p\u003e\u003cp\u003e\u0026gt;\u0026gt;Oral powder.\u003c\/p\u003e\u003cp\u003eAdults and adolescents (12-18 years): 1-2 single-dose sachets after meals and at bedtime.\u003c\/p\u003e\u003cp\u003eMethod of administration: Take the medicine orally without water.\u003c\/p\u003e\u003cp\u003eElderly: no dosage adjustment is necessary for this age group.\u003c\/p\u003e\u003cp\u003ePatients with renal insufficiency: the reduced ability to eliminate the exogenous saline supplement provided by antacids through urine may cause severe electrolyte imbalances.\u003c\/p\u003e\u003ch2\u003eSTORAGE\u003c\/h2\u003e\u003cp\u003eOral suspension and mint flavour oral suspension: do not store above 30 degrees C; store in the original package; do not refrigerate.\u003c\/p\u003e\u003cp\u003eMint flavour oral suspension in sachets: do not store above 25 degrees C; store in the original package; do not refrigerate.\u003c\/p\u003e\u003cp\u003eMint flavour chewable tablets: do not store above 30 degrees C; store in the original package.\u003c\/p\u003e\u003cp\u003eStrawberry flavour chewable tablets: do not store above 25 degrees C; store in the original package.\u003c\/p\u003e\u003cp\u003eOral powder: do not store above 25 degrees C; store in the original package.\u003c\/p\u003e\u003ch2\u003eWARNINGS\u003c\/h2\u003e\u003cp\u003eDo not use for prolonged treatment.\u003c\/p\u003e\u003cp\u003eIn adolescents (12-18 years), use only if strictly necessary.\u003c\/p\u003e\u003cp\u003eRenal insufficiency: in case of renal insufficiency, the medicine should be used with caution because the exogenous saline supplement provided by antacids may cause severe electrolyte imbalances.\u003c\/p\u003e\u003cp\u003eEach 500 mg + 267 mg tablet contains 123 mg (5.3 mmol) of sodium.\u003c\/p\u003e\u003cp\u003eEach 250 mg + 133.5 mg tablet contains 61.5 mg (2.65 mmol) of sodium.\u003c\/p\u003e\u003cp\u003eEach 10 ml dose of suspension contains 141 mg (6.2 mmol) of sodium.\u003c\/p\u003e\u003cp\u003eEach 500 mg + 267 mg single-dose sachet of oral powder contains 123 mg (5.3 mmol) of sodium.\u003c\/p\u003e\u003cp\u003eThis should be taken into account in cases where a particularly low-sodium diet is recommended, for example in some cases of congestive heart failure and renal impairment.\u003c\/p\u003e\u003cp\u003eEach 500 mg + 267 mg tablet contains 160 mg (1.6 mmol) of calcium carbonate.\u003c\/p\u003e\u003cp\u003eEach 250 mg + 133.5 mg tablet contains 80 mg (0.8 mmol) of calcium carbonate.\u003c\/p\u003e\u003cp\u003eEach 10 ml dose of suspension contains 160 mg (1.6 mmol) of calcium carbonate.\u003c\/p\u003e\u003cp\u003eEach 500 mg + 267 mg single-dose sachet of oral powder contains 160 mg (1.6 mmol) of calcium carbonate.\u003c\/p\u003e\u003cp\u003eCare should be taken when treating patients suffering from hypercalcaemia, nephrocalcinosis and recurrent calcium-containing kidney stones.\u003c\/p\u003e\u003cp\u003eThe tablets and oral powder contain aspartame, a source of phenylalanine: therefore, they should not be taken by patients suffering from phenylketonuria.\u003c\/p\u003e\u003cp\u003eThe suspension contains methyl parahydroxybenzoate and propyl parahydroxybenzoate, which may cause allergic reactions.\u003c\/p\u003e\u003cp\u003eGenerally, these are delayed-type reactions (contact dermatitis), or immediate reactions with urticaria and bronchospasm.\u003c\/p\u003e\u003cp\u003eDuration of treatment: if symptoms do not improve after seven days, the clinical picture should be re-evaluated.\u003c\/p\u003e\u003ch2\u003eINTERACTIONS\u003c\/h2\u003e\u003cp\u003eIt is advisable to allow an interval of at least two hours between the administration of this medicine and that of other medicines, especially tetracyclines, fluoroquinolones, iron salts, thyroid hormones, chloroquine, bisphosphonates, and estramustine.\u003c\/p\u003e\u003ch2\u003eUNDESIRABLE EFFECTS\u003c\/h2\u003e\u003cp\u003eBelow are the side effects of the product, organised according to the MedDRA organ system classification.\u003c\/p\u003e\u003cp\u003eThey are divided by frequency (very common (\u0026gt;= 1\/10), common (\u0026gt;= 1\/100 to \u0026lt;= 1\/10), uncommon (\u0026gt;= 1\/1,000 to \u0026lt;= 1\/100), rare (\u0026gt;= 1\/10,000 to 1\/1,000), very rare (\u0026lt;= 1\/10,000)).\u003c\/p\u003e\u003cp\u003eImmune system disorders.\u003c\/p\u003e\u003cp\u003eVery rare: anaphylactic or anaphylactoid reactions.\u003c\/p\u003e\u003cp\u003eHypersensitivity reactions (such as urticaria).\u003c\/p\u003e\u003cp\u003eRespiratory, thoracic and mediastinal disorders.\u003c\/p\u003e\u003cp\u003eVery rare: respiratory symptoms such as bronchospasm.\u003c\/p\u003e\u003cp\u003eGastrointestinal disorders.\u003c\/p\u003e\u003cp\u003eVery rare: flatulence, nausea.\u003c\/p\u003e\u003cp\u003eGeneral disorders and administration site conditions.\u003c\/p\u003e\u003cp\u003eVery rare: oedema.\u003c\/p\u003e\u003cp\u003eReporting suspected adverse reactions that occur after the authorisation of the medicine is important, as it allows for monitoring of the benefit\/risk ratio of the medicine.\u003c\/p\u003e\u003ch2\u003ePREGNANCY AND BREASTFEEDING\u003c\/h2\u003e\u003cp\u003eUse if strictly necessary.\u003c\/p\u003e","brand":"SalusMarket Salute e Benessere Online","offers":[{"title":"Default Title","offer_id":53461657256278,"sku":"24352205","price":7.76,"currency_code":"EUR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0968\/4507\/0678\/files\/Gaviscon-024352205.webp?v=1778239152"},{"product_id":"magnesia-bisurata-aromatic-40-pastiglie-acquista-online-su-farmaclick","title":"Magnesia Bisurata Aromatic 40 Tablets | Buy Online at Farmaclick","description":"\u003ch2\u003e\u003cfont style=\"vertical-align: inherit;\"\u003e\u003cfont style=\"vertical-align: inherit;\"\u003eWhat is Magnesia Bisurata Aromatic 40 Tablets\u003c\/font\u003e\u003c\/font\u003e\u003c\/h2\u003e\u003cp\u003e\u003cfont style=\"vertical-align: inherit;\"\u003e\u003cfont style=\"vertical-align: inherit;\"\u003eMagnesia Bisurata Aromatic tablets are indicated for the symptomatic treatment of \u003c\/font\u003e\u003c\/font\u003e\u003cstrong\u003e\u003cfont style=\"vertical-align: inherit;\"\u003e\u003cfont style=\"vertical-align: inherit;\"\u003eupper digestive tract\u003c\/font\u003e\u003c\/font\u003e\u003c\/strong\u003e\u003cfont style=\"vertical-align: inherit;\"\u003e\u003cfont style=\"vertical-align: inherit;\"\u003e disorders characterized by \u003c\/font\u003e\u003c\/font\u003e\u003cstrong\u003e\u003cfont style=\"vertical-align: inherit;\"\u003e\u003cfont style=\"vertical-align: inherit;\"\u003ehyperacidity\u003c\/font\u003e\u003c\/font\u003e\u003c\/strong\u003e\u003cfont style=\"vertical-align: inherit;\"\u003e\u003cfont style=\"vertical-align: inherit;\"\u003e.\u003c\/font\u003e\u003c\/font\u003e\u003c\/p\u003e\u003ch2\u003e\u003cfont style=\"vertical-align: inherit;\"\u003e\u003cfont style=\"vertical-align: inherit;\"\u003eActive Ingredients\u003c\/font\u003e\u003c\/font\u003e\u003c\/h2\u003e\u003cp\u003e\u003cfont style=\"vertical-align: inherit;\"\u003e\u003cfont style=\"vertical-align: inherit;\"\u003eEach tablet contains: Active ingredients: Magnesium carbonate 71.0 mg, Sodium bicarbonate 64.2 mg, Calcium carbonate 525.0 mg. Excipients with known effects: sucrose. For the full list of excipients, see section 6.1\u003c\/font\u003e\u003c\/font\u003e\u003c\/p\u003e\u003ch2\u003e\u003cfont style=\"vertical-align: inherit;\"\u003e\u003cfont style=\"vertical-align: inherit;\"\u003eExcipients\u003c\/font\u003e\u003c\/font\u003e\u003c\/h2\u003e\u003cp\u003e\u003cfont style=\"vertical-align: inherit;\"\u003e\u003cfont style=\"vertical-align: inherit;\"\u003eSodium saccharin, Sucrose, Corn starch, Calcium stearate, Peppermint essential oil.\u003c\/font\u003e\u003c\/font\u003e\u003c\/p\u003e\u003ch2\u003e\u003cfont style=\"vertical-align: inherit;\"\u003e\u003cfont style=\"vertical-align: inherit;\"\u003eDosage\u003c\/font\u003e\u003c\/font\u003e\u003c\/h2\u003e\u003cp\u003e\u003cfont style=\"vertical-align: inherit;\"\u003e\u003cfont style=\"vertical-align: inherit;\"\u003eOne tablet to be dissolved slowly in the mouth after meals and whenever pain is felt. If necessary, repeat after fifteen minutes. DO NOT EXCEED THE RECOMMENDED DOSES. Use only for short periods of treatment.\u003c\/font\u003e\u003c\/font\u003e\u003cb\u003e\u003cfont style=\"vertical-align: inherit;\"\u003e\u003cfont style=\"vertical-align: inherit;\"\u003ePatients with renal insufficiency:\u003c\/font\u003e\u003c\/font\u003e\u003c\/b\u003e\u003cfont style=\"vertical-align: inherit;\"\u003e\u003cfont style=\"vertical-align: inherit;\"\u003e The reduced ability to eliminate the exogenous saline supplement provided by antacids through urine can lead to severe electrolyte imbalances. Treatment with magnesium and calcium salts requires periodic monitoring of magnesemia and calcemia.\u003c\/font\u003e\u003c\/font\u003e\u003c\/p\u003e\u003ch2\u003e\u003cfont style=\"vertical-align: inherit;\"\u003e\u003cfont style=\"vertical-align: inherit;\"\u003eOverdose\u003c\/font\u003e\u003c\/font\u003e\u003c\/h2\u003e\u003cp\u003e\u003cfont style=\"vertical-align: inherit;\"\u003e\u003cfont style=\"vertical-align: inherit;\"\u003eExperience with deliberate overdose is very limited. As in all cases of overdose, treatment should be symptomatic, adopting general supportive measures.\u003c\/font\u003e\u003c\/font\u003e\u003c\/p\u003e\u003ch2\u003e\u003cfont style=\"vertical-align: inherit;\"\u003e\u003cfont style=\"vertical-align: inherit;\"\u003eContraindications\u003c\/font\u003e\u003c\/font\u003e\u003c\/h2\u003e\u003cp\u003e\u003cfont style=\"vertical-align: inherit;\"\u003e\u003cfont style=\"vertical-align: inherit;\"\u003eHypersensitivity to the active ingredients or to any of the excipients listed in section 6.1. Renal insufficiency. Do not administer simultaneously with tetracyclines (see section 4.5). Do not administer other medicines within 1 to 2 hours of using the product (see section 4.5). Administration of the medicine to children is not recommended.\u003c\/font\u003e\u003c\/font\u003e\u003c\/p\u003e\u003ch2\u003e\u003cfont style=\"vertical-align: inherit;\"\u003e\u003cfont style=\"vertical-align: inherit;\"\u003eInteractions\u003c\/font\u003e\u003c\/font\u003e\u003c\/h2\u003e\u003cp\u003e\u003cfont style=\"vertical-align: inherit;\"\u003e\u003cfont style=\"vertical-align: inherit;\"\u003eKeep in mind that antacids can, through various mechanisms, interfere with the oral administration of other drugs. In particular, the simultaneous administration of tetracyclines can lead to the formation of insoluble complexes, with a reduction in the absorption of these antibiotics. It is, however, advisable not to administer other medicines within 1 or 2 hours of using the product.\u003c\/font\u003e\u003c\/font\u003e\u003ci\u003e\u003cfont style=\"vertical-align: inherit;\"\u003e\u003cfont style=\"vertical-align: inherit;\"\u003eCombinations to be avoided:\u003c\/font\u003e\u003c\/font\u003e\u003c\/i\u003e\u003cfont style=\"vertical-align: inherit;\"\u003e\u003cfont style=\"vertical-align: inherit;\"\u003e- tetracyclines: formation of insoluble complexes with a reduction in the absorption and activity of these antibiotics.\u003c\/font\u003e\u003c\/font\u003e\u003ci\u003e\u003cfont style=\"vertical-align: inherit;\"\u003e\u003cfont style=\"vertical-align: inherit;\"\u003eInadvisable combination:\u003c\/font\u003e\u003c\/font\u003e\u003c\/i\u003e\u003cfont style=\"vertical-align: inherit;\"\u003e\u003cfont style=\"vertical-align: inherit;\"\u003e- quinidine: increase in plasma levels of quinidine and risk of overdose due to delayed excretion.\u003c\/font\u003e\u003c\/font\u003e\u003ci\u003e\u003cfont style=\"vertical-align: inherit;\"\u003e\u003cfont style=\"vertical-align: inherit;\"\u003eCombinations requiring precautions for use:\u003c\/font\u003e\u003c\/font\u003e\u003c\/i\u003e\u003cfont style=\"vertical-align: inherit;\"\u003e\u003cfont style=\"vertical-align: inherit;\"\u003e- indomethacin, phosphorus, dexamethasone, digitalis, iron salts, nitrofurantoin, lincomycin.\u003c\/font\u003e\u003c\/font\u003e\u003c\/p\u003e\u003ch2\u003e\u003cfont style=\"vertical-align: inherit;\"\u003e\u003cfont style=\"vertical-align: inherit;\"\u003eSide Effects\u003c\/font\u003e\u003c\/font\u003e\u003c\/h2\u003e\u003cp\u003e\u003cfont style=\"vertical-align: inherit;\"\u003e\u003cfont style=\"vertical-align: inherit;\"\u003eBased on the available bibliographic data, there are no side effects related to the specialty. Reporting of suspected adverse reactions. Reporting suspected adverse reactions after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are required to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/font\u003e\u003c\/font\u003e\u003c\/p\u003e\u003ch2\u003e\u003cfont style=\"vertical-align: inherit;\"\u003e\u003cfont style=\"vertical-align: inherit;\"\u003ePregnancy and Breastfeeding\u003c\/font\u003e\u003c\/font\u003e\u003c\/h2\u003e\u003cp\u003e\u003cfont style=\"vertical-align: inherit;\"\u003e\u003cfont style=\"vertical-align: inherit;\"\u003eWhile no adverse reactions are known, the product must be used under direct medical supervision in pregnant women and during breastfeeding.\u003c\/font\u003e\u003c\/font\u003e\u003c\/p\u003e\u003ch2\u003e\u003cfont style=\"vertical-align: inherit;\"\u003e\u003cfont style=\"vertical-align: inherit;\"\u003eWarnings and Precautions\u003c\/font\u003e\u003c\/font\u003e\u003c\/h2\u003e\u003cp\u003e\u003cfont style=\"vertical-align: inherit;\"\u003e\u003cfont style=\"vertical-align: inherit;\"\u003eIn patients with severe renal insufficiency, plasma magnesium levels tend to increase. In these patients, prolonged exposure to high doses of magnesium can lead to encephalopathy or worsening of dialysis-related osteomalacia. Caution should generally be exercised in patients with impaired renal function. In these patients, plasma levels of calcium and magnesium should be monitored regularly. In the case of low-sodium diets, it should be kept in mind that the product contains sodium salts. Important information about some ingredients: Magnesia Bisurata Aromatic contains sucrose. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency should not take this medicine.\u003c\/font\u003e\u003c\/font\u003e\u003c\/p\u003e\u003ch2\u003e\u003cfont style=\"vertical-align: inherit;\"\u003e\u003cfont style=\"vertical-align: inherit;\"\u003eStorage\u003c\/font\u003e\u003c\/font\u003e\u003c\/h2\u003e\u003cp\u003e\u003cfont style=\"vertical-align: inherit;\"\u003e\u003cfont style=\"vertical-align: inherit;\"\u003eThis medicine does not require any special storage conditions.\u003c\/font\u003e\u003c\/font\u003e\u003c\/p\u003e\u003ch2\u003e\u003cfont style=\"vertical-align: inherit;\"\u003e\u003cfont style=\"vertical-align: inherit;\"\u003eFormat\u003c\/font\u003e\u003c\/font\u003e\u003c\/h2\u003e\u003cp\u003e\u003cfont style=\"vertical-align: inherit;\"\u003e\u003cfont style=\"vertical-align: inherit;\"\u003ePack of 40 tablets.\u003c\/font\u003e\u003c\/font\u003e\u003c\/p\u003e","brand":"SalusMarket Salute e Benessere Online","offers":[{"title":"Default Title","offer_id":53499792916822,"sku":"5781036","price":11.21,"currency_code":"EUR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0968\/4507\/0678\/files\/magnesia.webp?v=1778224527"},{"product_id":"magnesia-bisurata-aromatic-80-compresse-acquista-online-su-farmaclick","title":"Magnesia Bisurata Aromatic 80 Tablets | Buy Online at Farmaclick","description":"\u003ch2\u003eWhat is Magnesia Bisurata Aromatic 80 Tablets\u003c\/h2\u003e\u003cp\u003e\u003cstrong\u003eMagnesia Bisurata Aromatic\u003c\/strong\u003e is a medication indicated for the symptomatic treatment of disorders of the upper \u003cstrong\u003edigestive tract\u003c\/strong\u003e characterized by \u003cstrong\u003ehyperacidity\u003c\/strong\u003e.\u003c\/p\u003e\u003ch2\u003eActive ingredients\u003c\/h2\u003e\u003cp\u003eEach tablet contains: Active ingredients: Magnesium Carbonate 71.0 mg, Sodium bicarbonate 64.2 mg, Calcium carbonate 525.0 mg. Excipients with known effects: sucrose. For the full list of excipients, see section 6.1\u003c\/p\u003e\u003ch2\u003eExcipients\u003c\/h2\u003e\u003cp\u003eSodium saccharin, Sucrose, Corn starch, Calcium stearate, Peppermint essential oil\u003c\/p\u003e\u003ch2\u003eContraindications\u003c\/h2\u003e\u003cp\u003eHypersensitivity to the active ingredients or to any of the excipients listed in section 6.1. Renal insufficiency. Do not administer simultaneously with Tetracyclines (see section 4.5). Do not administer other medications within 1 or 2 hours of using the product (see section 4.5). Administration of this medicine is not recommended in pediatric patients.\u003c\/p\u003e\u003ch2\u003eHow to take Magnesia Bisurata Aromatic\u003c\/h2\u003e\u003cp\u003eOne tablet to be dissolved slowly in the mouth after meals and whenever pain is felt. If necessary, repeat after a quarter of an hour. DO NOT EXCEED THE RECOMMENDED DOSES. Use only for short periods of treatment. Patients with renal insufficiency: The reduced ability to eliminate the exogenous saline supplement provided by antacids through urine can lead to potentially severe electrolyte imbalances. Treatment with magnesium and calcium salts requires periodic monitoring of magnesemia and calcemia.\u003c\/p\u003e\u003ch2\u003eStorage\u003c\/h2\u003e\u003cp\u003eThis medicine does not require any special storage conditions.\u003c\/p\u003e\u003ch2\u003eWarnings\u003c\/h2\u003e\u003cp\u003eIn patients with severe renal insufficiency, plasma magnesium levels tend to increase. In these patients, prolonged exposure to high doses of magnesium can lead to encephalopathies or worsening of dialysis-associated osteomalacia. Caution should generally be exercised in patients with impaired renal function. In these patients, plasma levels of calcium and magnesium should be checked regularly. In case of low-sodium diets, it must be kept in mind that the product contains sodium salts. Important information about some excipients: Magnesia Bisurata Aromatic contains sucrose. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency should not take this medicine.\u003c\/p\u003e\u003ch2\u003eInteractions\u003c\/h2\u003e\u003cp\u003eIt should be kept in mind that antacids can, through various mechanisms, interfere with the oral administration of other drugs. In particular, the simultaneous administration of Tetracyclines can result in insoluble complexes, reducing the absorption of these antibiotics. It is, in any case, advisable not to administer other medications within 1 or 2 hours of using the product. \u003ci\u003eAssociations to avoid:\u003c\/i\u003e- tetracyclines: formation of insoluble complexes with a reduction in the absorption and activity of these antibiotics. \u003ci\u003eAssociation not recommended:\u003c\/i\u003e- quinidine: increase in plasma levels of quinidine and risk of overdose due to decreased excretion. \u003ci\u003eAssociations requiring precautions for use:\u003c\/i\u003e- indomethacin, phosphorus, dexamethasone, digitalis, iron salts, nitrofurantoin, lincomycin.\u003c\/p\u003e\u003ch2\u003eSide effects\u003c\/h2\u003e\u003cp\u003eBased on available bibliographic data, there are no known side effects related to this specialty. Reporting of suspected adverse reactions. Reporting suspected adverse reactions after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are required to report any suspected adverse reaction via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\u003ch2\u003eOverdose\u003c\/h2\u003e\u003cp\u003eExperience with deliberate overdose is very limited. As in all cases of overdose, treatment should be symptomatic, adopting general supportive measures.\u003c\/p\u003e\u003ch2\u003ePregnancy and breastfeeding\u003c\/h2\u003e\u003cp\u003eAlthough no adverse reactions are known, in pregnant women and during breastfeeding, the product must be used under direct medical supervision.\u003c\/p\u003e\u003ch2\u003eFormat\u003c\/h2\u003e\u003cp\u003ePack of 80 tablets.\u003c\/p\u003e","brand":"SalusMarket Salute e Benessere Online","offers":[{"title":"Default Title","offer_id":53499792949590,"sku":"5781048","price":15.58,"currency_code":"EUR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0968\/4507\/0678\/files\/Magnesia-bisurata-aromatic-compresse-80cpr-005781048.jpg?v=1778224528"},{"product_id":"eugastrol-reflusso-14-compresse-20-mg-acquista-online-su-farmaclick","title":"Eugastrol Reflux 14 Tablets 20 Mg | Buy Online at Farmaclick","description":"\u003ch2\u003eEugastrol Reflux 20 mg - 14 Tablets\u003c\/h2\u003e\u003cp\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e: Eugastrol Reflux is a medication indicated for the treatment of gastroesophageal reflux symptoms, such as heartburn and acid regurgitation. It contains \u003cstrong\u003eesomeprazole\u003c\/strong\u003e 20 mg, a proton pump inhibitor (PPI) that reduces acid production in the stomach, providing rapid and prolonged relief from reflux symptoms. This treatment is indicated for adults and adolescents over 12 years of age.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eMain features\u003c\/strong\u003e:\u003c\/p\u003e\u003cul\u003e\n\n\u003cli\u003e\n\n\u003cstrong\u003eActive ingredient\u003c\/strong\u003e: Esomeprazole 20 mg per tablet.\u003c\/li\u003e\n\n\u003cli\u003e\n\n\u003cstrong\u003ePharmaceutical form\u003c\/strong\u003e: Gastro-resistant tablets.\u003c\/li\u003e\n\n\u003cli\u003e\n\n\u003cstrong\u003eIndications\u003c\/strong\u003e: Treatment of gastroesophageal reflux symptoms (e.g., heartburn, regurgitation).\u003c\/li\u003e\n\n\u003cli\u003e\n\n\u003cstrong\u003eAction\u003c\/strong\u003e: Reduces gastric acid production, alleviating symptoms associated with reflux.\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\u003cp\u003e\u003cstrong\u003eDosage\u003c\/strong\u003e:\u003c\/p\u003e\u003cul\u003e\n\n\u003cli\u003e\n\n\u003cstrong\u003eAdults and adolescents over 12 years\u003c\/strong\u003e: Take 1 tablet (20 mg) per day for a period that may range from 7 to 14 days, or as directed by a doctor.\u003c\/li\u003e\n\n\u003cli\u003eThe tablets should be swallowed whole with a glass of water, preferably before a meal.\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\u003cp\u003e\u003cstrong\u003eWarnings\u003c\/strong\u003e:\u003c\/p\u003e\u003cul\u003e\n\n\u003cli\u003eDo not use in case of hypersensitivity to esomeprazole or other proton pump inhibitors.\u003c\/li\u003e\n\n\u003cli\u003eConsult a doctor before use if you are pregnant or breastfeeding.\u003c\/li\u003e\n\n\u003cli\u003eDo not exceed the recommended dose without medical advice.\u003c\/li\u003e\n\n\u003cli\u003eKeep out of the reach of children.\u003c\/li\u003e\n\n\u003cli\u003eStore in a cool, dry place, away from direct light.\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\u003cp\u003e\u003cstrong\u003eFormat\u003c\/strong\u003e: Pack of 14 tablets.\u003c\/p\u003e","brand":"SalusMarket Salute e Benessere Online","offers":[{"title":"Default Title","offer_id":53500808102230,"sku":"40231021","price":6.7,"currency_code":"EUR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0968\/4507\/0678\/files\/Eugastrol_Reflusso_14_Compresse_20_Mg_c9868b77-0a60-4877-bf53-e92f6114da2f.webp?v=1778224972"},{"product_id":"gastroschoum-reflusso-20-mg-14-capsule-rigide","title":"Gastroschoum Reflusso 20 mg 14 Capsule Rigide","description":"\u003ch2\u003eCos'è Gastroschoum Reflusso 20 mg 14 Capsule Rigide\u003c\/h2\u003e\u003cp\u003eGastroSchoum Reflusso è indicato per il trattamento dei sintomi da reflusso (ad esempio bruciore di stomaco, rigurgito acido) negli adulti. Ogni capsula contiene 20 mg di omeprazolo. \u003cu\u003eEccipienti con effetti noti\u003c\/u\u003e Ciascuna capsula rigida contiene 225 mg di sodio. Per l’elenco completo degli eccipienti, vedere paragrafo 6.1\u003cbr\u003e\u003c\/p\u003e\u003ch3\u003eEccipienti\u003c\/h3\u003e\u003cp\u003e\u003cu\u003eContenuto della capsula:\u003c\/u\u003e Sodio idrogeno carbonato (E500ii), Sodio amido glicolato (Tipo A), Sodio stearilfumarato (E485). \u003cu\u003eCapsula:\u003c\/u\u003e Gelatina (E441), Ferro ossido rosso (E 172), Titanio diossido (E171).\u003c\/p\u003e\u003ch3\u003ePosologia\u003c\/h3\u003e\u003cp\u003e\u003cu\u003ePosologia\u003c\/u\u003e \u003ci\u003e\u003cu\u003eAdulti\u003c\/u\u003e \u003c\/i\u003eLa dose raccomandata è 20 mg (una capsula) una volta al giorno per 14 giorni. Potrebbe essere necessario assumere le capsule per 2-3 giorni consecutivi per ottenere il miglioramento dei sintomi. La maggior parte dei pazienti ottiene un sollievo completo dal bruciore di stomaco entro 7 giorni. Una volta ottenuta la completa scomparsa dei sintomi, il trattamento deve essere interrotto. \u003ci\u003e\u003cu\u003ePopolazioni particolari\u003c\/u\u003e \u003c\/i\u003e\u003ci\u003eCompromissione renale\u003c\/i\u003e Non è necessario alcun adattamento posologico nei pazienti con compromissione della funzionalità renale (vedere paragrafo 5.2). \u003ci\u003eCompromissione epatica\u003c\/i\u003e In pazienti con funzionalità epatica compromessa devono consultare un medico prima di prendere l’omeprazolo (vedere paragrafo 5.2). \u003ci\u003eAnziani\u003c\/i\u003e Non è necessario un aggiustamento della dose nei pazienti anziani (vedere paragrafo 5.2). \u003ci\u003ePopolazione pediatrica\u003c\/i\u003e L’utilizzo di GastroSchoum Reflusso non è raccomandato per l’uso in bambini e adolescenti al di sotto dei 18 anni di età. \u003cu\u003eModo di somministrazione\u003c\/u\u003e GastroSchoum Reflusso deve essere assunto a stomaco vuoto, almeno 30 minuti prima di mangiare e almeno due ore dopo l’ultimo pasto (vedere paragrafo 5.2). Per ottenere un effetto completo del medicinale, la capsula deve essere ingerita intera con mezzo bicchiere di acqua e non deve essere masticata o aperta.\u003c\/p\u003e\u003ch3\u003eConservazione\u003c\/h3\u003e\u003cp\u003eConservare a temperatura inferiore a 25°C. Conservare nella confezione originale per proteggere il medicinale dall’umidità.\u003c\/p\u003e\u003ch3\u003eAvvertenze\u003c\/h3\u003e\u003cp\u003eIn presenza di sintomi sospetti (ad esempio perdita di peso significativa e non voluta, vomito ricorrente, disfagia, ematemesi o melena) e quando l’ulcera gastrica è sospetta o presente, deve essere esclusa la presenza di una neoplasia prima di istituire il trattamento dal momento che la terapia può alleviare i sintomi e ritardare di conseguenza la diagnosi. La co-somministrazione di atazanavir con inibitori di pompa protonica non è raccomandata (vedere paragrafo 4.5). Se la combinazione di atazanavir con un inibitore di pompa protonica è considerata inevitabile, è raccomandato uno stretto monitoraggio clinico (ad esempio controllo della carica virale) in associazione all’aumento della dose di atazanavir a 400 mg con 100 mg di ritonavir; il dosaggio di 20 mg di omeprazolo non deve essere superato. L’omeprazolo è un inibitore del CYP2C19. Quando si inizia o si conclude un trattamento con omeprazolo, deve essere considerata la potenziale interazione con farmaci metabolizzati attraverso il CYP2C19. È stata osservata interazione tra clopidogrel e omeprazolo (vedere paragrafo 4.5). L’importanza clinica di questa interazione non è chiara. Come precauzione l’uso concomitante di omeprazolo e clopidogrel deve essere evitato. Reazioni avverse cutanee gravi (SCAR) tra cui sindrome di Stevens-Johnson (SJS), necrolisi epidermica tossica (TEN), reazione da farmaco con eosinofilia e sintomi sistemici (DRESS) e pustolosi esantematica acuta generalizzata (AGEP), le quali possono essere pericolose per la vita o fatali, sono state riportate molto raramente o raramente, rispettivamente in associazione al trattamento con omeprazolo. \u003cu\u003eLupus eritematoso cutaneo subacuto (LECS) \u003c\/u\u003eGli inibitori della pompa protonica sono associati a casi estremamente infrequenti di LECS. In presenza di lesioni, soprattutto sulle parti cutanee esposte ai raggi solari, e se accompagnate da artralgia, il paziente deve rivolgersi immediatamente al medico e l'operatore sanitario deve valutare l'opportunità di interrompere il trattamento con GastroSchoum Reflusso. La comparsa di LECS in seguito a un trattamento con un inibitore della pompa protonica può accrescere il rischio di insorgenza di LECS con altri inibitori della pompa protonica. Il trattamento con inibitori di pompa protonica può indurre un leggero aumento del rischio di infezioni gastrointestinali come \u003ci\u003eSalmonella\u003c\/i\u003e e \u003ci\u003eCampylobacter, e in pazienti ospedalizzati,\u003c\/i\u003e è possibile anche \u003ci\u003eClostridium difficile\u003c\/i\u003e (vedere paragrafo 5.1). \u003cu\u003eCompromissione renale \u003c\/u\u003eNefrite tubulo-interstiziale (TIN) acuta è stata osservata in pazienti che assumevano omeprazolo e può manifestarsi in qualsiasi momento durante la terapia con omeprazolo (vedere paragrafo 4.8). La nefrite tubulo-interstiziale acuta può evolvere in insufficienza renale. Omeprazolo deve essere interrotto in caso di TIN sospetta, e deve essere tempestivamente avviato un trattamento appropriato. \u003ci\u003eInterferenza con esami di laboratorio\u003c\/i\u003e Un livello aumentato di Cromogranina A (CgA) può interferire con gli esami diagnostici per tumori neuroendocrini. Per evitare tale interferenza, il trattamento con omeprazolo deve essere sospeso per almeno 5 giorni prima delle misurazioni della CgA (vedere paragrafo 5.1). Se i livelli di CgA e di gastrina non sono tornati entro il range di riferimento dopo la misurazione iniziale, occorre ripetere le misurazioni 14 giorni dopo l’interruzione del trattamento con inibitore della pompa protonica. I pazienti con sintomi a lungo termine ricorrenti di dispepsia o pirosi, devono consultare il loro medico ad intervalli regolari. Specialmente i pazienti di età superiore a 55 anni che assumono giornalmente medicinali per la dispepsia e la pirosi senza prescrizione medica (OTC), devono informare il farmacista o il medico. I pazienti devono essere istruiti a consultare un medico se: • Hanno avuto un’ulcera gastrica pregressa o interventi chirurgici gastrointestinali. • Sono stati in trattamento sintomatico continuo della dispepsia o della pirosi per 4 o più settimane. • Hanno ittero o malattia epatica grave. • Hanno età superiore a 55 anni con sintomi nuovi o recentemente cambiati. \u003cu\u003eSodio\u003c\/u\u003e Questo medicinale contiene 225 mg di sodio per capsula, che equivale all’11,2% del quantitativo massimo giornaliero di 2 g raccomandato dall’OMS per un adulto.\u003c\/p\u003e\u003ch3\u003eInterazioni\u003c\/h3\u003e\u003cp\u003e\u003cu\u003eEffetti di omeprazolo sulla farmacocinetica di altri principi attivi\u003c\/u\u003e \u003ci\u003e\u003cu\u003ePrincipi attivi con assorbimento pH dipendente\u003c\/u\u003e \u003c\/i\u003eLa riduzione dell’acidità gastrica durante il trattamento con omeprazolo può aumentare o ridurre l’assorbimento di principi attivi con assorbimento gastrico pH-dipendente. \u003ci\u003eNelfinavir, atazanavir\u003c\/i\u003e I livelli plasmatici di \u003ci\u003enelfinavir\u003c\/i\u003e e \u003ci\u003eatazanavir\u003c\/i\u003e sono ridotti in caso di co-somministrazione con omeprazolo. La concomitante somministrazione di omeprazolo con nelfinavir è controindicata (vedere paragrafo 4.3). La co-somministrazione di omeprazolo (40 mg una volta al giorno) riduce mediamente l’esposizione a nelfinavir di circa il 40% e l’esposizione media del metabolita farmacologicamente attivo M8 è ridotto di circa il 75-90%. L’interazione può anche coinvolgere l’inibizione del CYP2C19. La concomitante somministrazione di omeprazolo con atazanavir non è raccomandata (vedere paragrafo 4.4). La concomitante somministrazione di omeprazolo (40 mg una volta al giorno) e atazanavir 300 mg\/ritonavir 100 mg in volontari sani ha causato una riduzione del 75% dell’esposizione ad atazanavir. L’aumento della dose di atazanavir a 400 mg non ha compensato l’effetto di omeprazolo sull’esposizione ad atazanavir.La co-somministrazione di omeprazolo (20 mg una volta al giorno) con atazanavir 400 mg\/ritonavir 100 mg in volontari sani ha ridotto l’esposizione ad atazanavir approssimativamente del 30% in confronto a atazanavir 300 mg\/ritonavir 100 mg una volta al giorno. \u003ci\u003eDigossina\u003c\/i\u003e Il trattamento concomitante con omeprazolo (20 mg una volta al giorno) e digossina in soggetti sani ha aumentato la biodisponibilità della digossina del 10%. È stata raramente riportata tossicità per la digossina. Tuttavia, si deve prestare cautela quando omeprazolo è somministrato ad alte dosi a pazienti anziani. Il monitoraggio terapeutico della digossina deve quindi essere rinforzato. \u003ci\u003eClopidogrel\u003c\/i\u003e I risultati provenienti da studi su volontari sani hanno mostrato un’interazione farmacocinetica (PK)\/farmacodinamica (PD) tra clopidogrel (dose di carico 300 mg \/ dose di mantenimento giornaliera 75 mg) e omeprazolo (80 mg per via orale al giorno), risultante in una diminuita esposizione al metabolita attivo di clopidogrel pari mediamente al 46% e in una diminuzione della inibizione massima dell’aggregazione piastrinica (ADP indotta) pari mediamente al 16%. Sono stati riportati dati divergenti, provenienti da studi osservazionali e clinici, sulle implicazioni cliniche di una interazione PK\/PD di omeprazolo in termini di eventi cardiovascolari maggiori. A titolo precauzionale, l’uso concomitante di omeprazolo e clopidogrel deve essere scoraggiato (vedere paragrafo 4.4). \u003ci\u003eAltri principi attivi\u003c\/i\u003e L’assorbimento di posaconazolo, erlotinib, ketoconazolo e itraconazolo è significativamente ridotto e quindi l’efficacia clinica può essere compromessa. Per posaconazolo e erlotinib l’uso concomitante deve essere evitato. \u003ci\u003e\u003cu\u003eSostanze attive metabolizzate dal CYP2C19\u003c\/u\u003e \u003c\/i\u003eL’omeprazolo è un inibitore moderato del CYP2C19, il principale enzima metabolizzante l’omeprazolo. Quindi il metabolismo di sostanze attive anch’esse metabolizzate dal CYP2C19 può essere ridotto e l’esposizione sistematica a queste sostanze aumenta. Esempi di queste sostanze sono R-warfarin e altri antagonisti della vitamina K, cilostazolo, diazepam e fenitoina. \u003ci\u003eCilostazolo\u003c\/i\u003e L’omeprazolo, somministrato a dosi di 40 mg in soggetti sani in uno studio cross over, ha aumentato la Cmax e l’AUC di cilostazolo del 18% e 26% rispettivamente, e di uno dei suoi metaboliti attivi del 29% e 69% rispettivamente. \u003ci\u003eFenitoina\u003c\/i\u003e È raccomandato un monitoraggio dei livelli plasmatici di fenitoina durante le prime 2 settimane successive all’inizio del trattamento con omeprazolo e, se si attua un aggiustamento della dose di fenitoina, occorre un monitoraggio, e un ulteriore aggiustamento della dose deve essere effettuato alla fine del trattamento con omeprazolo. \u003cu\u003eMeccanismo sconosciuto\u003c\/u\u003e \u003ci\u003eSaquinavir\u003c\/i\u003e La somministrazione concomitante di omeprazolo con saquinavir\/ritonavir ha portato ad un aumento dei livelli plasmatici di saquinavir approssimativamente del 70% associato ad una buona tollerabilità nei pazienti affetti da HIV. \u003ci\u003eTacrolimus\u003c\/i\u003e È stato riportato un aumento dei livelli sierici di tacrolimus con la somministrazione concomitante di omeprazolo. Deve essere eseguito un monitoraggio rafforzato delle concentrazioni di tacrolimus così come della funzione renale (clearance della creatinina) e la dose di tacrolimus aggiustata, se necessario. \u003ci\u003eMetotressato\u003c\/i\u003e In alcuni pazienti è stato riportato che i livelli di metotressato aumentano se somministrato insieme a inibitori di pompa protonica. In presenza di alte dosi di metotressato, può essere necessario prendere in considerazione la sospensione temporanea di omeprazolo. \u003cu\u003eEffetti di altre sostanze attive sulla farmacocinetica dell’omeprazolo\u003c\/u\u003e \u003ci\u003eInibitori del CYP2C19 e\/o del CYP3A4\u003c\/i\u003e Dato che l’omeprazolo è metabolizzato dal CYP2C19 e dal CYP3A4, le sostanze attive conosciute per inibire il CYP2C19 o il CYP3A4 (quali claritromicina e voriconazolo) possono indurre un aumento dei livelli sierici dell’omeprazolo diminuendo la sua velocità di metabolizzazione. Il trattamento concomitante con voriconazolo porta ad un aumento all’esposizione di omeprazolo pari a più del doppio. Generalmente, dato che alte dosi di omeprazolo sono ben tollerate, non è richiesto un adattamento della dose. Tuttavia l’adattamento della dose deve essere considerato in pazienti con grave compromissione della funzionalità epatica, e nel caso di un trattamento a lungo termine. \u003ci\u003eInduttori del CYP2C19 e\/o del CYP3A4 \u003c\/i\u003eLe sostanze attive conosciute come induttori del CYP2C19 o del CYP3A4 o entrambi (come la rifampicina e l’erba di San Giovanni) possono portare ad una diminuzione dei livelli sierici di omeprazolo aumentando la velocità di metabolizzazione dell’omeprazolo.\u003c\/p\u003e\u003ch3\u003eSovradosaggio\u003c\/h3\u003e\u003cp\u003eSono disponibili informazioni limitate sugli effetti di un sovradosaggio di omeprazolo nell’uomo. In letteratura sono stati descritti dosi fino a 560 mg e sono state ricevute segnalazioni occasionali di dosi singole orali che hanno raggiunto i 2 400 mg di omeprazolo (120 volte la dose clinica abituale raccomandata). Sono stati riportati nausea, vomito, capogiri, dolore addominale, diarrea e cefalea. In singoli casi sono stati descritti anche apatia, depressione e confusione. I sintomi descritti in connessione con sovradosaggio di omeprazolo sono stati transitori e non è stata riportata alcuna grave conseguenza. La velocità di eliminazione è rimasta immodificata (cinetica di primo ordine) all’aumentare delle dosi. Il trattamento, se necessario, è sintomatico.\u003c\/p\u003e\u003ch3\u003eGravidanza e Allattamento\u003c\/h3\u003e\u003cp\u003e\u003cu\u003eGravidanza\u003c\/u\u003e I risultati di tre studi epidemiologici prospettici (più di 1 000 bambini esposti) indicano che non ci sono effetti avversi dell’omeprazolo sulla gravidanza o sulla salute del feto\/neonato. L’omeprazolo può essere usato in gravidanza. \u003cu\u003eAllattamento\u003c\/u\u003e L’omeprazolo è escreto nel latte materno ma è improbabile che influenzi il bambino se usato alle dosi terapeutiche. \u003cu\u003eFertilità\u003c\/u\u003e Gli studi sugli animali con la miscela racemica di omeprazolo, somministrata per via orale non indicano effetti sulla fertilità.\u003c\/p\u003e\u003ch3\u003eFormato\u003c\/h3\u003e\u003cp\u003eConfezione da 14 Capsule.\u003c\/p\u003e","brand":"SalusMarket Salute e Benessere Online","offers":[{"title":"Default Title","offer_id":53553985192278,"sku":"51151025","price":10.0,"currency_code":"EUR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0968\/4507\/0678\/files\/gastro-schoum-reflusso.webp?v=1778335301"}],"url":"https:\/\/farmasmart.shop\/en\/collections\/farmaci-da-banco-disturbi-gastrointestinali-acidita-bruciore-e-reflusso.oembed","provider":"SalusMarket Salute e Benessere Online","version":"1.0","type":"link"}